To kick LIfT’s science series off, we spoke to our CEO Alex Blyth regarding what makes IMANs different to regular neutrophils, what were...

London, 13 March 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...

LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the...

Award will support clinical manufacturing of the Company’s promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy

In this interview, Tony de Fougerolles describes his extensive experience in building out drug pipelines in the US and Europe, including...